Evidence method
Level · gp.fundamentals.debt_to_revenue
57390.66% · OPTIONAL · NOT_ENOUGH_HISTORY
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
BTAI · Jun 30, 2026
BioXcel Therapeutics, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001104659-26-095965General Corporate
Evidence method
Level · gp.fundamentals.capex_revenue_ratio
0.00% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-3350.55% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
51.67% · CORE · VALID
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
265.38% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.gross_margin
87.91% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
-5600.55% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
1738.46% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
196.70% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History16 statesHistory building
Sep 30, 20220/7 normalizedLevel 3Dec 31, 20220/7 normalizedLevel 3Mar 31, 20230/6 normalizedLevel 3Jun 30, 20230/6 normalizedLevel 3Sep 30, 20230/8 normalizedLevel 3Dec 31, 20230/8 normalizedLevel 3Mar 31, 20240/7 normalizedLevel 3Jun 30, 20240/7 normalizedLevel 3Sep 30, 20246/7 normalizedLevel 3Dec 31, 20246/7 normalizedLevel 3Mar 31, 20256/8 normalizedLevel 3Jun 30, 20256/8 normalizedLevel 3Sep 30, 20257/9 normalizedLevel 3Dec 31, 20257/9 normalizedLevel 3Mar 31, 20267/9 normalizedLevel 3Jun 30, 20267/9 normalizedLevel 3
Period transition
What moved in the state?
- Previous
- 48683.98%
- Current
- 57390.66%
- Delta
- 8706.68%
- Previous
- -5732.52%
- Current
- -3350.55%
- Delta
- 2381.97%
- Previous
- 22.62%
- Current
- 51.67%
- Delta
- 29.05%
- Previous
- 242.72%
- Current
- 265.38%
- Delta
- 22.67%
- Previous
- -37.38%
- Current
- 87.91%
- Delta
- 125.29%
- Previous
- -4962.62%
- Current
- -5600.55%
- Delta
- -637.93%
- Previous
- 1434.47%
- Current
- 1738.46%
- Delta
- 304.00%
- Previous
- 211.16%
- Current
- 196.70%
- Delta
- -14.46%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Compared To · Pharmaceutical Preparations peers →Transitioned To · BTAI Fundamental State →Transitioned To · BTAI BALANCE_SHEET_LEVERAGE_INCREASED →Transitioned To · BTAI CASH_GENERATION_INCREASED →Transitioned To · BTAI GROWTH_INCREASED →Transitioned To · BTAI INVENTORY_PRESSURE_INCREASED →Transitioned To · BTAI MARGIN_INCREASED →Transitioned To · BTAI PROFITABILITY_DECREASED →Transitioned To · BTAI R_AND_D_INTENSITY_INCREASED →Transitioned To · BTAI SBC_INTENSITY_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.